Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-01-05 00:00:00 ET · period of report 2024-01-03 · accession 0001714899-24-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-05 | 2024-01-03 | DNLI | Watts Ryan J. | Pres, CEO, Dir | A - Grant | $0.00 | +89.5K | 273.0K | +49% | $0 |
| D | 2024-01-05 | 2024-01-03 | DNLI | Watts Ryan J. | Pres, CEO, Dir | A - Grant | $0.00 | +268.6K | 268.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-03 | A | A | 89,520 | $0.00 | 272,957 | D | — | — | (F1) Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. (F2) Includes 221,897 RSU's as of January 4, 2024. |
| 2 | Derivative | Stock Option (right to buy) | 2024-01-03 | A | A | 268,560 | $0.00 | 268,560 | D | $20.33 · — to 2034-01-02 | 268,560 Common Stock | (F4) 25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. |